

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## **Bragatston study protocol: a multicenter cohort study on automated quantification of cardiovascular calcifications on radiotherapy planning CT-scans for cardiovascular risk prediction in breast cancer patients**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028752
Article Type:	Protocol
Date Submitted by the Author:	21-Dec-2018
Complete List of Authors:	Emaus, Marleen; University Medical Center Utrecht, Işgum, Ivana; University Medical Center Utrecht, Image Sciences Institute van Velzen, Sanne; University Medical Center Utrecht, Image Sciences Institute van den Bongard, Desire; University Medical Center Utrecht, Department of Radiation Oncology Gernaat, Sofie; University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care Lessmann, Nikolas; University Medical Center Utrecht, Image Sciences Institute Sattler, Margriet; Erasmus MC Cancer Institute, Department of Radiation Oncology Teske, Arco; University Medical Center Utrecht, Department of Cardiology Penninkhof, Joan; Erasmus MC Cancer Institute, Department of Radiation Oncology Meijer, Hanneke; Radboudumc, Department of Radiation Oncology Pignol, Jean-Philippe; Dalhousie University, Department of Radiation Oncology Verkooijen, Helena; University Medical Center Utrecht, Imaging Division
Keywords:	Breast cancer, Cardiovascular disease, Coronary artery calcifications, Prediction, Deep learning algorithm, Radiotherapy planning CT-scan

SCHOLARONE™  
Manuscripts

**TITLE**

Bragatston study protocol: a multicenter cohort study on automated quantification of cardiovascular calcifications on radiotherapy planning CT-scans for cardiovascular risk prediction in breast cancer patients

**CORRESPONDING AUTHOR**

Helena Marieke Verkooijen

University Medical Center Utrecht, Imaging Division

PO Box 85500

3508 GA Utrecht

The Netherlands

Email: H.M.Verkooijen@umcutrecht.nl

Phone: +31 88 75 59575

**AUTHORS**

Marleen J. Emaus<sup>1</sup>

m.j.emaus@umcutrecht.nl

Ivana Išgum<sup>2</sup>

I.Isgum@umcutrecht.nl

Sanne G.M. van Velzen<sup>2</sup>

S.G.M.vanVelzen@umcutrecht.nl

H.J.G. Desirée van den Bongard<sup>3</sup>

D.vandenBongard@umcutrecht.nl

Sofie A.M. Gernaat<sup>4</sup>

S.A.M.Gernaat@umcutrecht.nl

Nikolas Lessmann<sup>2</sup>

N.Lessmann@umcutrecht.nl

Margriet G.A. Sattler<sup>5</sup>

m.sattler@erasmusmc.nl

Arco J. Teske<sup>6</sup>

A.J.Teske-2@umcutrecht.nl

Joan Penninkhof<sup>5</sup>

j.penninkhof@erasmusmc.nl

Hanneke Meijer<sup>7</sup>

Hanneke.Meijer@radboudumc.nl

Jean-Philippe Pignol<sup>8</sup> Jean-Philippe.Pignol@nshealth.ca

Helena M. Verkooijen<sup>1,9</sup> H.M.Verkooijen@umcutrecht.nl

Bragatston study group

<sup>1</sup>Imaging Division, University Medical Center Utrecht, Utrecht, the Netherlands

<sup>2</sup>Image Sciences Institute, University Medical Center Utrecht, Utrecht, the Netherlands

<sup>3</sup>Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands

<sup>4</sup>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands

<sup>5</sup>Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

<sup>6</sup>Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands

<sup>7</sup>Department of Radiation Oncology, Radboudumc, Nijmegen, the Netherlands

<sup>8</sup>Department of Radiation Oncology, Dalhousie University, Halifax, Nova Scotia, Canada

<sup>9</sup>Utrecht University, Utrecht, the Netherlands

## WORD COUNT

3,781

## KEYWORDS

Breast cancer; Cardiovascular disease; Coronary artery calcifications; Prediction; Deep learning algorithm; Radiotherapy planning CT-scan

## ABSTRACT

**Introduction** Cardiovascular disease (CVD) is an important cause of death in breast cancer survivors. Some breast cancer treatments including anthracyclines, trastuzumab and radiotherapy can increase the risk of CVD, especially for patients with pre-existing CVD risk factors. Early identification of patients at increased CVD risk may allow switching to less cardiotoxic treatments, active surveillance or treatment of CVD risk factors. One of the strongest independent CVD risk factors is the presence and extent of coronary artery calcifications (CAC). In clinical practice, CAC are generally quantified on electrocardiogram (ECG)-triggered cardiac computed tomography (CT)-scans. Breast cancer patients treated with radiotherapy routinely undergo radiotherapy planning CT-scans of the chest, and those scans could provide the opportunity to routinely assess CAC before a potentially cardiotoxic treatment. The Bragatston study aims to investigate the association between calcifications in the coronary arteries, aorta and heart valves (hereinafter called 'cardiovascular calcifications') measured automatically on planning CT-scans of breast cancer patients and CVD risk.

**Methods and analysis** In a first step, we will optimize and validate a deep learning algorithm for automated quantification of cardiovascular calcifications on planning CT-scans of breast cancer patients. Then, in a multicenter cohort study (University Medical Center Utrecht, Erasmus MC Cancer Institute, Radboudumc), the association between cardiovascular calcifications measured on planning CT-scans of breast cancer patients ( $n \approx 16,000$ ) and incident (non-)fatal CVD events will be evaluated. To assess the added predictive value of these calcifications over traditional CVD risk factors and treatment characteristics, a case-cohort analysis will be performed among all cohort members diagnosed with a CVD event during follow-up ( $n \approx 200$ ) and a random sample of the baseline cohort ( $n \approx 600$ ).

1  
2  
3 **Ethics and dissemination** The Institutional Review Boards of the participating hospitals  
4  
5 decided that the Medical Research Involving Human Subjects Act does not apply. Findings  
6  
7 will be published in peer-reviewed journals and presented at conferences.  
8  
9

10 **Trial registration number** NCT03206333  
11  
12  
13  
14  
15

## 16 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

17  
18

- 19     ▪ For each patient, an individual cardiovascular risk score will be automatically  
20         calculated on routine radiotherapy planning CT-scans
- 21     ▪ Cardiovascular calcifications will be measured using an automated deep learning  
22         algorithm in an objective, reproducible and fast manner
- 23     ▪ A case-cohort design will be used to estimate absolute risks, which will facilitate  
24         clinical (shared) decision making
- 25     ▪ Outcome data will be obtained through linkage with high quality national registries
- 26     ▪ Due to the relatively short follow-up, the number of long-term cardiovascular  
27         disease events will be limited which may lead to an underestimation of the  
28         prognostic value of cardiovascular calcifications  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Over the past 25 years, breast cancer mortality rates have declined substantially following improvements in therapy and early detection due to screening.[1, 2] This, in combination with high breast cancer incidence rates, has resulted in a considerable number of breast cancer survivors.[3] In 2012, there were 6,2 million women worldwide who had been diagnosed with breast cancer in the previous five years and many of them are assumed to die of causes unrelated to breast cancer.[3, 4] This implies a strong need for research on prevention of breast cancer treatment-induced complications, such as cardiovascular diseases (CVDs).

CVD is the leading cause of death in women worldwide accounting for one third of all global female deaths in 2015.[5] Also in breast cancer patients it is an important cause of mortality.[4] Colzani et al. showed that in breast cancer patients 12% of all deaths within 10 years after diagnosis were attributed to CVD, and in the subgroup of elderly patients (>65 years) 24% of deaths were CVD-related.[6] Radiotherapy and some systemic therapies such as chemotherapy (anthracyclines) and immunotherapy (trastuzumab) can increase the risk of CVD, in particular in patients with pre-existing CVD risk factors.[7-13] Early and accurate identification of patients at increased risk of CVD, i.e. before breast cancer treatment is administered, is important to reduce the burden of CVD in breast cancer survivors.

One of the strongest independent CVD risk factors is the presence and extent of coronary artery calcifications (CAC).[14] In clinical practice, CAC are quantified on electrocardiogram (ECG)-synchronized cardiac computed tomography (CT) scans without contrast. All breast cancer patients that receive radiation therapy (>60% of breast cancer patients[15]) routinely undergo a radiotherapy (RT) planning CT-scan of the chest. Although these scans do not have the same image quality for the detection of CAC as cardiac scans due to the absence of ECG triggering and lower image resolution, it has been shown that CAC can still be routinely assessed on these scans.[16, 17] CAC was measured using an automated deep learning algorithm which has the advantage of being an objective, reproducible and fast method. One in four breast cancer patients had some degree of

1  
2  
3 CAC.[16, 17] Based on information from radiotherapy medical records, 28% of patients with  
4 severe CAC did not have other traditional CVD risk factors.[16] However, evidence on  
5 whether CAC measured on RT planning CT-scans is a predictor of CVD risk is still lacking. In  
6 addition, the prognostic value of CAC has not yet been investigated in patients with breast  
7 cancer.  
8  
9  
10  
11  
12

13  
14 If breast cancer patients at increased risk of CVD can be identified, these patients may  
15 benefit from less cardiotoxic treatment strategies, for example adaptation of RT target  
16 volumes or technique, chemotherapy dose reduction or switching to less harmful regimes, an  
17 intervention on CVD risk factors including lifestyle changes or pharmacoprevention, and from  
18 close monitoring for early detection of cardiotoxicity during and after breast cancer treatment  
19 using imaging techniques or biomarkers.[18-30] In that way the burden of CVD among breast  
20 cancer survivors could be reduced and lead to a better overall survival rate and improved  
21 quality of life.  
22  
23  
24  
25  
26  
27  
28  
29

30 The Bragatston study aims to investigate the association between CAC measured  
31 automatically on RT planning CT-scans using a deep learning algorithm and CVD risk among  
32 breast cancer patients. Furthermore, thoracic aorta calcifications (TAC), aortic valve  
33 calcifications (AVC) and mitral valve calcifications (MVC) will also be analyzed as they are  
34 also associated with CVD risk.[31-33] In this manuscript, we report the design of the  
35 Bragatston study.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## 47 **METHODS AND ANALYSIS**

### 48 **Study aims**

49 The Bragatston study is divided into three work packages (WP):  
50  
51  
52

53 WP 1: This diagnostic package aims to optimize and validate an in-house developed  
54 automated deep learning algorithm to measure the presence and extent of CAC, TAC, AVC  
55  
56  
57  
58  
59  
60



1  
2  
3 and MVC (hereinafter called 'cardiovascular calcifications') on RT planning CT-scans of  
4 breast cancer patients.  
5  
6  
7

8 WP 2: This etiological package will evaluate the association between cardiovascular  
9 calcifications measured automatically on RT planning CT-scans and the risk of (non-)fatal  
10 CVD events in breast cancer patients. It will also evaluate if the association is modified by  
11 type of (neo-)adjuvant breast cancer treatment.  
12  
13  
14  
15  
16

17 WP 3: This prognostic package will assess the added value of cardiovascular calcifications  
18 measured automatically on RT planning CT-scans over traditional CVD risk factors and  
19 breast cancer treatment characteristics to predict (non-)fatal CVD events in breast cancer  
20 patients.  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Study design and population**

30  
31 For WP 1 and 2, the Bragatston study uses a cohort design (Figure 1). The cohort will  
32 include all patients with non-metastatic primary breast cancer treated with radiotherapy at the  
33 University Medical Center Utrecht in Utrecht, the Erasmus MC Cancer Institute in Rotterdam  
34 and the Radboudumc in Nijmegen ( $n \approx 16,000$ ), the Netherlands. Patients with a prevalent  
35 cancer diagnosis will be excluded. From these institutions RT planning CT-scans and clinical  
36 data will be collected starting from the time CT radiotherapy planning was introduced, which  
37 was in 2005 (University Medical Center Utrecht) and 2006 (Erasmus MC Cancer Institute  
38 and Radboudumc) until the end of 2016.  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 For WP 3, a case-cohort study will be conducted.[34] The case-cohort study will include  
49 all cohort members diagnosed with a CVD event during follow-up, called hereafter cases. In  
50 addition, a random sample will be selected at baseline from the cohort to serve as control. To  
51 increase statistical power, a case-to-control ratio of 1:3 will be applied leading to a random  
52 sample of approximately 600 patients.  
53  
54  
55  
56  
57  
58  
59  
60

## Data collection procedures

### Automatic calcification quantification

Cardiovascular calcifications will be measured automatically using a calcium scoring algorithm previously developed in our group.[35] The algorithm uses two consecutive convolutional neural networks (CNN) to label voxels as calcifications in the coronary arteries (left main coronary artery, left anterior descending artery, left circumflex artery and right coronary artery), as well as calcifications in the thoracic aorta and the aortic and mitral valve (leaflets and annulus). The first CNN is used on a large field of view to enable learning from contextual spatial information. This CNN is able to identify calcified voxels and label them according to their anatomical location. The second CNN uses a smaller field of view and analyses the detailed local texture. This CNN can differentiate the true atherosclerotic calcifications among the candidates detected by the first CNN (Figure 2).

The algorithm was initially developed to analyse low-dose lung cancer screening CT-scans.[35] Hence the algorithm has been modified to be able to measure calcifications on RT planning CT-scans of breast cancer patients. This procedure has been described in detail elsewhere.[17] The first results show that automatic calcification quantification is possible on RT planning CT-scans of breast cancer patients. Reproducibility of automatically versus manually measured calcium scores was high with linearly weighted kappa values  $\geq 0.84$  and intraclass correlation coefficients  $\geq 0.94$ . [17] For the current project, we will further develop the method to ensure its robustness with respect to image acquisition parameters and thereby enable its applicability in multicenter settings.

CAC, TAC, AVC and MVC will be expressed in volume scores (in  $\text{mm}^3$ ). For routine ECG-gated cardiac CT-scans, CAC is expressed in the Agatston score which also takes the calcification density into account.[36] The CT-scans used in this project are ungated and therefore we will report CAC as modified Agatston score.[37] These modified Agatston scores will be categorized into the Agatston classification consisting of five categories: 0, 1-10, 11-100, 101-400, >400 Agatston units.

## Reference library of manual calcification quantification

Reference standard for calcium scoring will be defined by manual calcium scoring. Calcifications in the coronary arteries, the aorta and heart valves will be manually identified and labelled. As is standard procedure, 3D region growing will be used with a threshold of 130 Hounsfield Units (HU).[36] Manual annotation will be performed by observers who will be trained and supervised by a radiologist (PAJ) with more than 10 years of experience in cardiac CT. Subsequently, manually annotated calcifications will be quantified to determine calcium scores. Those reference annotations will be used to train the algorithm and to evaluate its performance.

## Tumor and treatment characteristics and CVD risk factors

Tumor and breast cancer treatment data will be obtained through linkage with the Netherlands Cancer Registry (NCR) hosted by the Netherlands Comprehensive Cancer Organisation.[38]

For WP 3, detailed data on breast cancer treatment and traditional CVD risk factors present at breast cancer diagnosis will be extracted from hospital and general practice medical records. The following traditional CVD risk factor data will be collected: age, sex, hypertension, hypercholesterolaemia, diabetes, rheumatoid arthritis, smoking and body mass index. Local project members of the participating hospitals will perform linkage with the NCR and will collect medical record data.

## Assessment of outcome

The primary outcome is the incidence of (non-)fatal CVD events, which is defined as hospitalization or death from CVD. Death from CVD will be recorded if it is primary cause of

1  
2  
3 death, meaning this is the disease that leads to death. CVD outcomes will be captured  
4 through linkage with Dutch Hospital Data (DHD), the Dutch Heart Registration (DHR), the  
5 Dutch Population Register (PR) and the National Cause of Death Register (CDR).  
6  
7

8  
9 DHD collects nationwide medical and administrative data for all inpatient and day  
10 hospital-care in the Netherlands (i.e. Hospital Discharge Register). The DHD uses the  
11 International Classification of Disease 9<sup>th</sup> revision (ICD-9).[39] According to this classification,  
12 CVD will be categorized as diseases of the circulatory system (ICD-codes 390-459) and will  
13 be further subcategorized into the following subcategories: hypertensive disease (401-405),  
14 ischemic heart disease (410-414), pericarditis (420), valvular dysfunction (424),  
15 cardiomyopathy (425), arrhythmia (426-427), heart failure (428) and cerebrovascular disease  
16 (430-438) and other. Linkage with the DHD will be facilitated by Statistics Netherlands using  
17 the record identification number.[40] This number is based on a combination of date of birth,  
18 sex and postal code and is assigned to each resident in the Netherlands.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 For a more complete data collection on incident CVD, additional linkage with the DHR  
31 will be performed.[41] The DHR collects data on cardiac interventions (e.g. percutaneous  
32 coronary intervention) and cardiothoracic surgery (e.g. coronary artery bypass surgery, heart  
33 valve surgery). Linkage will be performed using a combination of identifiers including date of  
34 birth, sex and maiden name.  
35  
36  
37  
38  
39

40 Data on vital status will be obtained from the Dutch Population Register (PR). Causes of  
41 death will be obtained from the CDR maintained by Statistics Netherlands. The register  
42 contains information on all primary and secondary causes of death from all deceased  
43 persons registered in the Netherlands. Causes of death are classified according to ICD-  
44 10.[42] CVD mortality will be categorized as diseases of the circulatory system (ICD-codes  
45 I00-I99) and will be further subcategorized into the following subcategories: hypertensive  
46 diseases (I10-13), ischemic heart diseases (I20-I25), pericarditis (I30-32), valvular  
47 dysfunction (I34-38), cardiomyopathy (I42), arrhythmia (I44-49), heart failure (I50) and  
48 cerebrovascular diseases (I60-I69) and other. Linkage with the PR and CDR will be provided  
49 by Statistics Netherlands. Linkage will be performed by local project members of the  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 participating hospitals. Registries are complete until the end of 2016 (DHD and DHR) or 2017  
4  
5 (CDR).  
6  
7  
8  
9

### 10 **Power calculation**

11  
12  
13 The cohort will consist of approximately 16,000 breast cancer patients (University Medical  
14 Center Utrecht:  $n \approx 8,000$ ; Erasmus MC Cancer Institute:  $n \approx 5,000$ ; Radboudumc:  $n \approx 3,000$ ). A  
15 preliminary study was conducted within the prospective breast cancer cohort Utrecht cohort  
16 for Multiple BREast cancer intervention studies and Long-term evaluation (UMBRELLA).[16,  
17 43] In total, 561 UMBRELLA patients were included and 24% of them had CAC (i.e. Agatston  
18 score  $> 0$ ).[16] By including at least 12,000 patients with an average follow-up of 4 years,  
19 2,880 patients will be expected to have CAC. Assuming 4.5% risk of CVD events after 4  
20 years of follow-up, 130 CVD events among patients with CAC are expected.[44] In the 9,120  
21 patients without CAC, with a CVD risk of 1.5% after 4 years, 137 CVD events are expected.  
22 Based on the expected number of at least 200 cases of CVD, a maximum of 20 predictor  
23 variables can be selected for predicting CVD without risk of overfitting.[45]  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **Statistical analysis**

41  
42  
43 For WP 1, reliability and agreement will be assessed between automatically and manually  
44 determined calcium scores. Agreement between continuous calcium scores will be assessed  
45 using Bland-Altman plots and between calcium score categories using proportional  
46 agreement. To determine reliability, intraclass correlation coefficients will be calculated for  
47 continuous calcium scores. Reliability of calcium categories will be evaluated as Cohen's  
48 linearly weighted kappa.  
49  
50  
51  
52  
53  
54

55  
56 For WP 2, (non-)fatal CVD event rates per 1,000 person years will be calculated for  
57 each calcium score category and plotted using Kaplan-Meier survival curves. Differences  
58  
59  
60

1  
2  
3 between categories will be tested with log-rank tests. Cox proportional hazard models will be  
4 used to examine the association between calcium scores and (non-)fatal CVD events.  
5 Results will be expressed as hazard ratios with their corresponding 95% confidence  
6 intervals. Follow-up time will be the underlying time variable starting from the date of RT  
7 planning CT-scan and ending at the date of diagnosis of (non-)fatal CVD event or censoring.  
8 Censored observations will include non-cardiovascular death, diagnosis of other cancers or  
9 end of follow-up, whichever came first. Models will be adjusted for age at RT planning CT-  
10 scan and calendar year of RT planning CT-scan. To assess possible effect modification of  
11 the association between cardiovascular calcifications and CVD risk by cardiotoxic  
12 chemotherapy, left-sided radiotherapy or trastuzumab, stratified analysis will be performed. If  
13 evidence for effect modification will be found, models with and without the cross-product term  
14 for calcium score and cardiotoxic treatment, will be compared using a log-likelihood ratio test.  
15 In order to assess the potential effect of competing events precluding the outcome of  
16 interest, sensitivity analyses will be conducted comprising cumulative incidence analysis and  
17 competing risk survival analysis as described by Fine and Gray.[46]

18  
19 For WP 3, in univariable cox regression analysis, we will identify which patient  
20 characteristics, traditional CVD risk factors or breast cancer treatment characteristics are  
21 associated with the risk of CVD events. As proposed by Prentice, a weighted cox regression  
22 model will be applied to account for the case-cohort design.[34] Subsequently, a prediction  
23 model will be developed including patient characteristics, traditional CVD risk factors and  
24 treatment characteristics. In a second prediction model, calcium scores will be added and the  
25 incremental value of calcium scores in CVD risk prediction will be evaluated by comparing  
26 discrimination (c-statistics) and reclassification (net reclassification index). To take into  
27 account the potential effect of missing data, a sensitivity analysis will be conducted imputing  
28 missing values of traditional CVD risk factor and breast cancer treatment variables using  
29 multiple imputation.[47]

## **Patient and public involvement**

We will conduct a survey among 100 UMBRELLA patients to explore their preferences regarding disclosure of calcium scores and corresponding CVD risk. Themes that will be included in the questionnaire are patient's knowledge about CVD risk following a breast cancer diagnosis, the patient's wish to be informed about CVD risk and preferences on way of disclosure of CVD risk. The survey will be developed in collaboration with the Dutch Patient Advocacy Group, a joint initiative from the Dutch Breast Cancer Research Group (BOOG) and the Dutch Breast Cancer Association (BVN).[48,49] We will inform breast cancer patients about the results of this project by means of newsletters and presentations at patient conferences, for example at the annual UMBRELLA patient conference.

## **ETHICS AND DISSEMINATION**

The study protocol has been reviewed by the Institutional Review Boards (IRBs) of the University Medical Center Utrecht (reference number: 16-721/C), Erasmus MC Cancer Institute Rotterdam (MEC-2017-1125) and Radboudumc (2017-3847). The IRBs decided that the Medical Research Involving Human Subjects Act does not apply to the study. The requirement for informed consent was waived in accordance with the Code of Conduct for Medical Research developed by the Federation of Medical Scientific Societies.[50] Analyses will be performed in a secure environment of Statistics Netherlands. The dataset will be anonymized by Statistics Netherlands. The results of the Bragatston study will be published in international peer-reviewed journals and presented at scientific conferences.

## **DISCUSSION**

The Dutch Bragatston study has been set up to optimize and validate an automated deep learning algorithm for the identification of breast cancer patients at high risk of CVD based on

1  
2  
3 the presence of cardiovascular calcifications on RT planning CT. Most breast cancer  
4 treatment guidelines and survival prediction tools mainly focus on tumor characteristics while  
5 other patient characteristics are hardly taken into account. In the era of personalized  
6 medicine, given the high burden of CVD in breast cancer patients it is critical to incorporate  
7 patient CVD risk factors in treatment decisions to find an optimal balance between cancer  
8 control and cardiotoxicity. Automated measurement of cardiovascular calcifications on RT  
9 planning CT-scans may be an elegant solution, because RT planning CT-scans are readily  
10 available imaging data and therefore there is no additional (radiation exposure) harm to  
11 patients and only a minimal financial burden to society when calcium scores are measured  
12 on these scans.

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24 If we find that cardiovascular calcifications measured on RT planning CT-scans are  
25 predictors of CVD risk, the next step will be to investigate how to act on this information and  
26 how to disclose this information to the patient. The dilemma of disclosing calcium scores and  
27 corresponding CVD risk lies in the fact that there is no evidence yet regarding effective risk  
28 reducing interventions. Thus far, no randomized trials have been conducted on the  
29 effectiveness of calcium score-based treatment strategies with CVD morbidity and mortality  
30 reduction as outcome measure.[51] The Risk Or Benefit IN Screening for CArdiovascular  
31 diseases (ROBINSICA) trial is the first ongoing randomized controlled trial investigating the  
32 value of CAC imaging followed by preventive treatment in reducing coronary heart disease-  
33 related mortality and morbidity.[52] In the intervention arm, participants with a CAC Agatston  
34 score above 100 will be treated with statins and angiotensin converting enzyme (ACE)  
35 inhibitors, independent of their blood cholesterol level and blood pressure value. The results  
36 of the ROBINSICA trial might provide important insights potentially relevant for breast cancer  
37 patients with moderate or high CAC score.

38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54 The importance of our study lies in the possibility to introduce targeted preventive  
55 interventions to reduce treatment related CVD. Those include minimization of the mean  
56 radiotherapy heart dose, for example by application of volumetric modulated arc therapy  
57  
58  
59  
60



1  
2  
3 (VMAT) instead of the standard three dimensional conformal radiation therapy (3DCRT).[53]  
4  
5 Furthermore, chemotherapy-induced cardiotoxicity may be reduced by switching to less  
6  
7 harmful regimens, for example an anthracycline free regime consisting of docetaxel,  
8  
9 carboplatin and trastuzumab has been described for human epidermal growth factor receptor  
10  
11 2 (HER-2) positive breast cancer as a more heart friendly alternative to the standard  
12  
13 regimen.[19, 21, 27] Another strategy is to screen for and treat modifiable cardiovascular risk  
14  
15 factors like high blood pressure, diabetes mellitus and high cholesterol levels.[18-20]  
16  
17 Additionally, increased awareness needs to be generated among physicians to identify and  
18  
19 refer breast cancer patients at high risk for CVD to a cardio-oncologist. Cardio-oncology is a  
20  
21 new upcoming discipline focused on cardiovascular care for cancer patients which comprises  
22  
23 CVD risk stratification, close monitoring during and after cancer treatment by means of  
24  
25 imaging techniques or circulating biomarkers and management of a possible CVD event.[18,  
26  
27  
28 20, 27]

29  
30 In conclusion, over the last two decades, advances in breast cancer treatments has led  
31  
32 to improved survival rates. However, these treatments can increase the risk of CVD. To  
33  
34 optimize the individual benefit and risk evaluation of treatment options, we propose to  
35  
36 evaluate the inclusion of information on patient CVD risk. Automated measurement of  
37  
38 cardiovascular calcifications on routinely obtained RT planning CT-scans may be an  
39  
40 inexpensive, fast and accurate solution. The Bragatston study will determine the correlation  
41  
42 between those RT planning CT detected cardiovascular calcifications and the occurrence of  
43  
44 CVD events.  
45  
46  
47  
48  
49  
50

## 51 **AUTHORS' CONTRIBUTIONS**

52  
53  
54 MJE, II, SGMV, HJGDB, SAMG, NL, MGAS, AJT, JP, HM, J-PP, HMV set up the study and  
55  
56 protocols. MJE, II, SGMV, SAMG and HMV drafted the manuscript. All authors read and  
57  
58 approved the final manuscript.  
59  
60

## FUNDING

The work is supported by the Dutch Cancer Society grant number UU 2015-7947.

## COMPETING INTERESTS

Ivana Išgum: Disclosures not related to the present article: Dr. Išgum received research grants from 1) Pie Medical Imaging BV; 2) the Netherlands Organization for Health Research and Development (ZonMw) with participation of PIE Medical Imaging BV; 3) the Dutch Technology Foundation (STW) within Deep Learning for Medical Image Analysis (DLMedia) with participation of Pie Medical Imaging BV and Philips Healthcare; 4) Dutch Technology Foundation (STW) with participation of Pie Medical Imaging BV and 3mensio Medical Imaging. In addition, Dr. Išgum has a patent, US Patent Application Number 15/933854, with royalties paid and she is scientific founder and a shareholder of Quantib-U BV.

Joan Penninkhof: Disclosures not related to the present article: Dr. Penninkhof received grants from 1) Accuray Inc, Sunnyvale, USA; 2) Elekta AB, Stockholm, Sweden.

## WORD COUNT

3,781

## ACKNOWLEDGEMENTS

The authors gratefully acknowledge the Dutch Cancer Society for the financial support.

They also acknowledge the members of the Bragatston study group who serve as scientific advisors: Drs. Rhodé M. Bijlsma, Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands. Dr. Erwin L.A. Blezer, Imaging Division, University

1  
2  
3 Medical Center Utrecht, Utrecht, the Netherlands. Prof. dr. Michiel L. Bots, Julius Center for  
4 Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the  
5 Netherlands and Utrecht University, Utrecht, the Netherlands. Drs. Henrike J. Bretveld,  
6 Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht,  
7 the Netherlands. Dr. Maartje J. Hoening, Department of Medical Oncology, Erasmus MC  
8 Cancer Institute, Rotterdam, the Netherlands. Prof. dr. Luca Incrocci, Department of  
9 Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Prof. dr.  
10 Pim A. de Jong, Department of Radiology, University Medical Center Utrecht, Utrecht, the  
11 Netherlands and Utrecht University, Utrecht, the Netherlands. Prof. dr. Tim Leiner,  
12 Department of Radiology, University Medical Center Utrecht, Utrecht, the Netherlands and  
13 Utrecht University, Utrecht, the Netherlands. Dr. Julia J. van Tol-Geerdink, Department of  
14 Radiation Oncology, Radboudumc, Nijmegen, the Netherlands. Dr. Ilonca Vaartjes, Julius  
15 Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht,  
16 the Netherlands. Dr. Wouter B. Veldhuis, Department of Radiology, University Medical  
17 Center Utrecht, Utrecht, the Netherlands. Dr. Janneke Verloop, Department of Research,  
18 Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands. Prof. dr.  
19 Max A. Viergever, Image Sciences Institute, University Medical Center Utrecht, Utrecht, the  
20 Netherlands and Utrecht University, Utrecht, the Netherlands. Prof. dr. Frank L.J. Visseren,  
21 Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, the  
22 Netherlands and Utrecht University, Utrecht, the Netherlands. Dr. Hester Wessels,  
23 Department of Corporate Communications, University Medical Center Utrecht, Utrecht, the  
24 Netherlands.

## 51 52 REFERENCES

53  
54  
55 1 Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on  
56 mortality from breast cancer. *N Engl J Med* 2005;353:1784-92.  
57  
58  
59  
60

1  
2  
3 2 Plevritis SK, Munoz D, Kurian AW, et al. Association of Screening and Treatment With  
4 Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. *JAMA*  
5 2018;319:154-64.  
6  
7  
8

9  
10 3 Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and  
11 Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency  
12 for Research on Cancer; 2013. <http://globocan.iarc.fr> (accessed 17 May 2018).  
13  
14  
15

16  
17 4 Gernaat SAM, Ho PJ, Rijnberg N, et al. Risk of death from cardiovascular disease following  
18 breast cancer: a systematic review. *Breast Cancer Res Treat* 2017;164:537-55.  
19  
20

21  
22 5 World Health Organization: Global health estimates 2015: deaths by cause, age and sex,  
23 by country and by region, 2000-2015  
24 [http://www.who.int/healthinfo/global\\_burden\\_disease/estimates/en/index1.html](http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html) (accessed 17  
25 May 2018).  
26  
27  
28  
29

30  
31 6 Colzani E, Liljegren A, Johansson AL, et al. Prognosis of patients with breast cancer:  
32 causes of death and effects of time since diagnosis, age, and tumor characteristics. *J Clin*  
33 *Oncol* 2011;29:4014-21.  
34  
35  
36

37  
38 7 Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after  
39 radiotherapy for breast cancer. *N Engl J Med* 2013;368:987-98.  
40  
41

42  
43 8 Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-  
44 year survivors of breast cancer. *J Natl Cancer Inst* 2007;99:365-75.  
45  
46  
47

48 9 Moslehi J. The cardiovascular perils of cancer survivorship. *N Engl J Med* 2013;368:1055-  
49 6.  
50  
51

52  
53 10 Harris EE. Cardiac mortality and morbidity after breast cancer treatment. *Cancer Cont*  
54 2008;15:120-9.  
55  
56

57  
58 11 Accordino MK, Neugut AI, Hershman DL. Cardiac effects of anticancer therapy in the  
59 elderly. *J Clin Oncol* 2014;32:2654-61.  
60

1  
2  
3 12 Brower V. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer. *J*  
4 *Natl Cancer Inst* 2013;105:835-6.  
5  
6

7  
8 13 Boekel NB, Jacobse JN, Schaapveld M, et al. Cardiovascular disease incidence after  
9 internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer.  
10 *Br J Cancer* 2018;119:408-41.  
11  
12  
13

14 14 Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for  
15 improvement in cardiovascular risk assessment in intermediate-risk individuals. *JAMA*  
16 2012;308:788-95.  
17  
18  
19  
20

21  
22 15 Mittmann N, Seung SJ, Liu N, et al. Population-based utilization of radiation therapy by a  
23 Canadian breast cancer cohort. *Curr Oncol* 2014;21:e715-7.  
24  
25

26  
27 16 Gernaat SA, Isgum I, de Vos BD, et al. Automatic Coronary Artery Calcium Scoring on  
28 Radiotherapy Planning CT Scans of Breast Cancer Patients: Reproducibility and Association  
29 with Traditional Cardiovascular Risk Factors. *PloS one* 2016;11:e0167925.  
30  
31  
32

33  
34 17 Gernaat SAM, van Velzen SGM, Koh V, et al. Automatic quantification of calcifications in  
35 the coronary arteries and thoracic aorta on radiotherapy planning CT scans of Western and  
36 Asian breast cancer patients. *Radiother Oncol* 2018;127:487-92.  
37  
38  
39

40  
41 18 Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on  
42 cancer treatments and cardiovascular toxicity developed under the auspices of the ESC  
43 Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular  
44 toxicity of the European Society of Cardiology (ESC). *Eur Heart J* 2016;37:2768-801.  
45  
46  
47  
48

49  
50 19 Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies:  
51 a position statement from the Heart Failure Association of the European Society of  
52 Cardiology. *Eur J Heart Fail* 2011;13:1-10.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 20 Armenian SH, Lacchetti C, Barac A, et al. Prevention and Monitoring of Cardiac  
4 Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical  
5 Practice Guideline. *J Clin Oncol* 2017;35:893-911.  
6  
7

8  
9  
10 21 Levis BE, Binkley PF, Shapiro CL. Cardiotoxic effects of anthracycline-based therapy:  
11 what is the evidence and what are the potential harms? *Lancet Oncol* 2017;18:e445-e56.  
12  
13

14  
15 22 Ades F, Zardavas D, Pinto AC, et al. Cardiotoxicity of systemic agents used in breast  
16 cancer. *Breast* 2014;23:317-28.  
17  
18

19  
20 23 Witteles RM, Bosch X. Myocardial Protection During Cardiotoxic Chemotherapy.  
21 *Circulation* 2015;132:1835-45.  
22  
23

24  
25 24 Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity  
26 with chemotherapy: a systematic review and meta-analysis. *Eur J Cancer* 2013;49:2900-9.  
27  
28

29  
30 25 Bruzzaniti V, Abate A, Pinnaro P, et al. Dosimetric and clinical advantages of deep  
31 inspiration breath-hold (DIBH) during radiotherapy of breast cancer. *J Exp Clin Cancer Res*  
32 2013;32:88.  
33  
34

35  
36  
37 26 Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by  
38 chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. *Ann*  
39 *Oncol* 2012;23(Suppl 7:vii155-66).  
40  
41

42  
43  
44 27 Comprehensive Cancer Centre the Netherlands (IKNL). Nation-wide Breast Cancer  
45 Guideline. <https://www.oncoline.nl/borstkanker> (accessed 17 May 2018).  
46  
47

48  
49  
50 28 Dang CT, Yu AF, Jones LW, et al. Cardiac Surveillance Guidelines for Trastuzumab-  
51 Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter. *J Clin*  
52 *Oncol* 2016;34:1030-3.  
53  
54

55  
56  
57 29 Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments:  
58 Epidemiology, detection, and management. *CA Cancer J Clin* 2016;66:309-25.  
59  
60

1  
2  
3 30 Correa C, Harris EE, Leonardi MC, et al. Accelerated Partial Breast Irradiation: Executive  
4 summary for the update of an ASTRO Evidence-Based Consensus Statement. *Pract Radiat*  
5 *Oncol* 2017;7:73-9.  
6  
7  
8

9  
10 31 Tison GH, Guo M, Blaha MJ, et al. Multisite extracoronary calcification indicates  
11 increased risk of coronary heart disease and all-cause mortality: The Multi-Ethnic Study of  
12 Atherosclerosis. *J Cardiovasc Comput Tomogr* 2015;9:406-14.  
13  
14  
15

16  
17 32 Jacobs PC, Prokop M, van der Graaf Y, et al. Comparing coronary artery calcium and  
18 thoracic aorta calcium for prediction of all-cause mortality and cardiovascular events on low-  
19 dose non-gated computed tomography in a high-risk population of heavy smokers.  
20 *Atherosclerosis* 2010;209:455-62.  
21  
22  
23  
24

25  
26 33 Willemink MJ, Takx RA, Isgum I, et al. Prognostic value of heart valve calcifications for  
27 cardiovascular events in a lung cancer screening population. *Int J Cardiovasc Imaging*  
28 2015;31:1243-9.  
29  
30  
31  
32

33  
34 34 Prentice RL. A Case-Cohort Design for Epidemiologic Cohort Studies and Disease  
35 Prevention Trials. *Biometrika* 1986;73:1-11.  
36  
37  
38

39 35 Lessmann N, van Ginneken B, Zreik M, et al. Automatic Calcium Scoring in Low-Dose  
40 Chest CT Using Deep Neural Networks With Dilated Convolutions. *IEEE Trans Med Imaging*  
41 2018;37:615-25.  
42  
43  
44  
45

46 36 Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium  
47 using ultrafast computed tomography. *J Am Coll Cardiol* 1990;15:827-32.  
48  
49  
50

51 37 Chiles C, Duan F, Gladish GW, et al. Association of Coronary Artery Calcification and  
52 Mortality in the National Lung Screening Trial: A Comparison of Three Scoring Methods.  
53 *Radiology* 2015;276:82-90.  
54  
55  
56

57  
58 38 Netherlands Comprehensive Cancer Organisation. <https://www.iknl.nl> (accessed 17 May  
59 2018).  
60

1  
2  
3 39 World Health Organization. Manual of the International Statistical Classification of  
4 Diseases Injuries and Causes of Death. Ninth Revision, vol 1. Geneva: World Health  
5 Organization, 1977.  
6  
7  
8

9  
10 40 Statistics Netherlands. <https://www.cbs.nl/en-gb> (accessed 17 May 2018).  
11

12  
13 41 Dutch Heart Registration. <https://www.nederlandsehartregistratie.nl> (accessed 17 May  
14 2018).  
15  
16

17  
18 42 World Health Organization. International Statistical Classification of Diseases, Injuries and  
19 Related Health Problems. Tenth Revision. Geneva: World Health Organization, 1992.  
20  
21

22  
23 43 Young-Afat DA, van Gils CH, van den Bongard H, et al. The Utrecht cohort for Multiple  
24 BREast cancer intervention studies and Long-term eValuation (UMBRELLA): objectives,  
25 design, and baseline results. *Breast Cancer Res Treat* 2017;164:445-50.  
26  
27  
28

29  
30 44 Blaha MJ, Budoff MJ, DeFilippis AP, et al. Associations between C-reactive protein,  
31 coronary artery calcium, and cardiovascular events: implications for the JUPITER population  
32 from MESA, a population-based cohort study. *Lancet* 2011;378:684-92.  
33  
34  
35

36  
37 45 Peduzzi P, Concato J, Feinstein AR, et al. Importance of events per independent variable  
38 in proportional hazards regression analysis II. Accuracy and precision of regression  
39 estimates. *J Clin Epidemiol* 1995;48:1503-10.  
40  
41  
42

43  
44 46 Fine JP GR. A proportional hazards model for the subdistribution of a competing risk. *J*  
45 *Am Stat Assoc* 1999;94:496-509.  
46  
47

48  
49 47 Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: J. Wiley & Sons;  
50 1987.  
51  
52

53  
54 48 Dutch Breast Cancer Research Group (BOOG). <https://www.boogstudycenter.nl>  
55 (accessed 20 December 2018).  
56  
57  
58  
59  
60



1  
2  
3 49 Dutch Breast Cancer Association (BVN). <https://borstkanker.nl> (accessed 20 December  
4 2018).

5  
6  
7  
8 50 Federation of Medical Scientific Societies. Code of conduct.  
9 [https://www.federa.org/sites/default/files/bijlagen/coreon/gedragscode\\_gezondheidsonderzoek.pdf](https://www.federa.org/sites/default/files/bijlagen/coreon/gedragscode_gezondheidsonderzoek.pdf) (accessed 17 May 2018).

10  
11  
12  
13  
14  
15 51 Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of  
16 cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology  
17 Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the*  
18 *Am Coll Cardiol* 2010;56:e50-103.

19  
20  
21  
22  
23  
24 52 Vonder M, van der Aalst CM, Vliegenthart R, et al. Coronary Artery Calcium Imaging in  
25 the ROBINSCA Trial: Rationale, Design, and Technical Background. *Acad Radiol*  
26 2017;25:118-28.

27  
28  
29  
30  
31 53 Taylor CW, Kirby AM. Cardiac Side-effects From Breast Cancer Radiotherapy. *Clin Oncol*  
32 *(R Coll Radiol)* 2015;27:621-9.

## 33 34 35 36 37 38 39 40 41 42 **FIGURE TITLES AND LEGENDS**

### 43 44 45 **Figure 1:**

46  
47  
48 Title: Flowchart Bragatston study

49  
50  
51 Legend: Abbreviations: CDR = National cause of death register; CT = computed tomography;  
52 CVD = cardiovascular disease; DHD = Dutch Hospital Data; DHR = Dutch Heart  
53 Registration; NCR = Netherlands Cancer Registry; PR = Dutch Population Register; RT =  
54 radiotherapy  
55  
56  
57  
58  
59  
60



1  
2  
3 **Figure 2:**  
4


5  
6 Title: Example of automatic calcification quantification on radiotherapy planning CT-scan  
7  
8 using our deep learning algorithm  
9

10  
11 Legend: Radiotherapy planning CT-scan image showing calcifications in the left anterior  
12  
13 descending artery (in red) and left circumflex artery (in green). Abbreviations: LAD = left  
14  
15 anterior descending artery; LCX = left circumflex artery  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

BRAGATSTON





Title: Example of automatic calcification quantification on radiotherapy planning CT-scan using our deep learning algorithm

Legend: Radiotherapy planning CT-scan image showing calcifications in the left anterior descending artery (in red) and left circumflex artery (in green). Abbreviations: LAD = left anterior descending artery; LCX = left circumflex artery

197x149mm (600 x 600 DPI)

**STROBE Statement**

Checklist of items that should be included in reports of observational studies

Section/Topic	Item No	Recommendation	Reported on Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 3
		(b) Provide in the abstract an informative and balanced summary of what was will be done and what was found	3, 4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5,6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
Variables	7	(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	NA
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
		Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-11
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-11
Bias	9	Describe any efforts to address potential sources of bias	7, 8, 12
Study size	10	Explain how the study size was arrived at	11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8, 10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	11,12
		(b) Describe any methods used to examine subgroups and interactions	12
		(c) Explain how missing data were addressed	12
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	12
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	
(e) Describe any sensitivity analyses	12		

Section/Topic	Item No	Recommendation	Reported on Page No
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	NA**
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	NA**
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	NA**
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA**
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA**
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	NA**
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	NA**
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	NA**
Generalisability	21	Discuss the generalisability (external validity) of the study results	NA**
<b>Other Information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

\*\*Not applicable, because this paper is just about the study protocol

# BMJ Open

## Bragatston study protocol: a multicenter cohort study on automated quantification of cardiovascular calcifications on radiotherapy planning CT-scans for cardiovascular risk prediction in breast cancer patients

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028752.R1
Article Type:	Protocol
Date Submitted by the Author:	25-May-2019
Complete List of Authors:	Emaus, Marleen; University Medical Center Utrecht, Işgum, Ivana; University Medical Center Utrecht, Image Sciences Institute van Velzen, Sanne; University Medical Center Utrecht, Image Sciences Institute van den Bongard, Desirée; University Medical Center Utrecht, Department of Radiation Oncology Gernaat, Sofie; University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care Lessmann, Nikolas; University Medical Center Utrecht, Image Sciences Institute Sattler, Margriet; Erasmus MC Cancer Institute, Department of Radiation Oncology Teske, Arco; University Medical Center Utrecht, Department of Cardiology Penninkhof, Joan; Erasmus MC Cancer Institute, Department of Radiation Oncology Meijer, Hanneke; Radboudumc, Department of Radiation Oncology Pignol, Jean-Philippe; Dalhousie University, Department of Radiation Oncology Verkooijen, Helena; University Medical Center Utrecht, Imaging Division
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Cardiovascular medicine, Epidemiology, Oncology, Radiology and imaging
Keywords:	Breast cancer, Cardiovascular disease, Coronary artery calcifications, Prediction, Deep learning algorithm, Radiotherapy planning CT-scan

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**TITLE**

Bragatston study protocol: a multicenter cohort study on automated quantification of cardiovascular calcifications on radiotherapy planning CT-scans for cardiovascular risk prediction in breast cancer patients

**CORRESPONDING AUTHOR**

Helena Marieke Verkooijen

University Medical Center Utrecht, Imaging Division

PO Box 85500

3508 GA Utrecht

The Netherlands

Email: H.M.Verkooijen@umcutrecht.nl

Phone: +31 88 75 59575

**AUTHORS**

Marleen J. Emaus<sup>1</sup>

marleen\_emaus@hotmail.com

Ivana Išgum<sup>2</sup>

I.Isgum@umcutrecht.nl

Sanne G.M. van Velzen<sup>2</sup>

S.G.M.vanVelzen@umcutrecht.nl

H.J.G. Desirée van den Bongard<sup>3</sup>

D.vandenBongard@umcutrecht.nl

Sofie A.M. Gernaat<sup>4</sup>

S.A.M.Gernaat@umcutrecht.nl

Nikolas Lessmann<sup>2</sup>

N.Lessmann@umcutrecht.nl

Margriet G.A. Sattler<sup>5</sup>

m.sattler@erasmusmc.nl

Arco J. Teske<sup>6</sup>

A.J.Teske-2@umcutrecht.nl

Joan Penninkhof<sup>5</sup>

j.penninkhof@erasmusmc.nl

Hanneke Meijer<sup>7</sup>

Hanneke.Meijer@radboudumc.nl

Jean-Philippe Pignol<sup>8</sup> Jean-Philippe.Pignol@nshealth.ca

Helena M. Verkooijen<sup>1,9</sup> H.M.Verkooijen@umcutrecht.nl

Bragatston study group

<sup>1</sup>Imaging Division, University Medical Center Utrecht, Utrecht, the Netherlands

<sup>2</sup>Image Sciences Institute, University Medical Center Utrecht, Utrecht, the Netherlands

<sup>3</sup>Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands

<sup>4</sup>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands

<sup>5</sup>Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

<sup>6</sup>Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands

<sup>7</sup>Department of Radiation Oncology, Radboudumc, Nijmegen, the Netherlands

<sup>8</sup>Department of Radiation Oncology, Dalhousie University, Halifax, Nova Scotia, Canada

<sup>9</sup>Utrecht University, Utrecht, the Netherlands

## WORD COUNT

3,784

## KEYWORDS

Breast cancer; Cardiovascular disease; Coronary artery calcifications; Prediction; Deep learning algorithm; Radiotherapy planning CT-scan

## ABSTRACT

**Introduction** Cardiovascular disease (CVD) is an important cause of death in breast cancer survivors. Some breast cancer treatments including anthracyclines, trastuzumab and radiotherapy can increase the risk of CVD, especially for patients with pre-existing CVD risk factors. Early identification of patients at increased CVD risk may allow switching to less cardiotoxic treatments, active surveillance or treatment of CVD risk factors. One of the strongest independent CVD risk factors is the presence and extent of coronary artery calcifications (CAC). In clinical practice, CAC are generally quantified on electrocardiogram (ECG)-triggered cardiac computed tomography (CT)-scans. Breast cancer patients treated with radiotherapy routinely undergo radiotherapy planning CT-scans of the chest, and those scans could provide the opportunity to routinely assess CAC before a potentially cardiotoxic treatment. The Bragatston study aims to investigate the association between calcifications in the coronary arteries, aorta and heart valves (hereinafter called 'cardiovascular calcifications') measured automatically on planning CT-scans of breast cancer patients and CVD risk.

**Methods and analysis** In a first step, we will optimize and validate a deep learning algorithm for automated quantification of cardiovascular calcifications on planning CT-scans of breast cancer patients. Then, in a multicenter cohort study (University Medical Center Utrecht, Erasmus MC Cancer Institute, Radboudumc), the association between cardiovascular calcifications measured on planning CT-scans of breast cancer patients ( $n \approx 16,000$ ) and incident (non-)fatal CVD events will be evaluated. To assess the added predictive value of these calcifications over traditional CVD risk factors and treatment characteristics, a case-cohort analysis will be performed among all cohort members diagnosed with a CVD event during follow-up ( $n \approx 200$ ) and a random sample of the baseline cohort ( $n \approx 600$ ).

**Ethics and dissemination** The Institutional Review Boards of the participating hospitals decided that the Medical Research Involving Human Subjects Act does not apply. Findings will be published in peer-reviewed journals and presented at conferences.

1  
2  
3 **Trial registration number** NCT03206333  
4  
5  
6  
7

8  
9 **STRENGTHS AND LIMITATIONS OF THIS STUDY**  
10

- 11  
12     ▪ For each patient, an individual cardiovascular risk score will be automatically  
13         calculated on routine radiotherapy planning CT-scans  
14  
15     ▪ Cardiovascular calcifications will be measured using an automated deep learning  
16         algorithm in an objective, reproducible and fast manner  
17  
18     ▪ A case-cohort design will be used to estimate absolute risks, which will facilitate  
19         clinical (shared) decision making  
20  
21     ▪ Outcome data will be obtained through linkage with high quality national registries  
22  
23     ▪ Due to the relatively short follow-up, the number of long-term cardiovascular disease  
24         events will be limited which may lead to an underestimation of the prognostic value  
25         of cardiovascular calcifications  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Over the past 25 years, breast cancer mortality rates have declined substantially following improvements in therapy and early detection due to screening.[1, 2] This, in combination with high breast cancer incidence rates, has resulted in a considerable number of breast cancer survivors.[3] In 2012, there were 6,2 million women worldwide who had been diagnosed with breast cancer in the previous five years and many of them are assumed to die of causes unrelated to breast cancer.[3, 4] This implies a strong need for research on prevention of breast cancer treatment-induced complications, such as cardiovascular diseases (CVDs).

CVD is the leading cause of death in women worldwide accounting for one third of all global female deaths in 2015.[5] Also in breast cancer patients it is an important cause of mortality.[4] Colzani et al. showed that in breast cancer patients 12% of all deaths within 10 years after diagnosis were attributed to CVD, and in the subgroup of elderly patients (>65 years) 24% of deaths were CVD-related.[6] Radiotherapy and some systemic therapies such as chemotherapy (anthracyclines) and immunotherapy (trastuzumab) can increase the risk of CVD, in particular in patients with pre-existing CVD risk factors.[7-13] Early and accurate identification of patients at increased risk of CVD, i.e. before breast cancer treatment is administered, is important to reduce the burden of CVD in breast cancer survivors.

One of the strongest independent CVD risk factors is the presence and extent of coronary artery calcifications (CAC).[14] In clinical practice, CAC are quantified on electrocardiogram (ECG)-synchronized cardiac computed tomography (CT) scans without contrast. All breast cancer patients that receive radiation therapy (>60% of breast cancer patients[15]) routinely undergo a radiotherapy (RT) planning CT-scan of the chest. Although these scans do not have the same image quality for the detection of CAC as cardiac scans due to the absence of ECG triggering and lower image resolution, it has been shown that CAC can still be routinely assessed on these scans.[16, 17] CAC was measured using an automated deep learning algorithm which has the advantage of being an objective, reproducible and fast method. One in four breast cancer patients had some degree of CAC.[16, 17] Based on information from

1  
2  
3 radiotherapy medical records, 28% of patients with severe CAC did not have other traditional  
4  
5 CVD risk factors.[16] However, evidence on whether CAC measured on RT planning CT-scans  
6  
7 is a predictor of CVD risk is still lacking. In addition, the prognostic value of CAC has not yet  
8  
9 been investigated in patients with breast cancer.  
10

11  
12 If breast cancer patients at increased risk of CVD can be identified, these patients may  
13  
14 benefit from less cardiotoxic treatment strategies, for example adaptation of RT target volumes  
15  
16 or technique, chemotherapy dose reduction or switching to less harmful regimes, an  
17  
18 intervention on CVD risk factors including lifestyle changes or pharmacoprevention, and from  
19  
20 close monitoring for early detection of cardiotoxicity during and after breast cancer treatment  
21  
22 using imaging techniques or biomarkers.[18-30] In that way the burden of CVD among breast  
23  
24 cancer survivors could be reduced and lead to a better overall survival rate and improved  
25  
26 quality of life.  
27

28  
29 The Bragatston study aims to investigate the association between CAC measured  
30  
31 automatically on RT planning CT-scans using a deep learning algorithm and CVD risk among  
32  
33 breast cancer patients. Furthermore, thoracic aorta calcifications (TAC), aortic valve  
34  
35 calcifications (AVC) and mitral valve calcifications (MVC) will also be analyzed as they are also  
36  
37 associated with CVD risk.[31-33] In this manuscript, we report the design of the Bragatston  
38  
39 study.  
40  
41  
42  
43  
44

## 45 **METHODS AND ANALYSIS**

### 46 47 **Study aims**

48  
49 The Bragatston study is divided into three work packages (WP):  
50  
51

52  
53 WP 1: This diagnostic package aims to optimize and validate an in-house developed  
54  
55 automated deep learning algorithm to measure the presence and extent of CAC, TAC, AVC  
56  
57 and MVC (hereinafter called 'cardiovascular calcifications') on RT planning CT-scans of breast  
58  
59 cancer patients.  
60

1  
2  
3 WP 2: This etiological package will evaluate the association between cardiovascular  
4 calcifications measured automatically on RT planning CT-scans and the risk of (non-)fatal CVD  
5 events in breast cancer patients. It will also evaluate if the association is modified by type of  
6 (neo-)adjuvant breast cancer treatment.  
7  
8  
9  
10

11  
12 WP 3: This prognostic package will assess the added value of cardiovascular calcifications  
13 measured automatically on RT planning CT-scans over traditional CVD risk factors and breast  
14 cancer treatment characteristics to predict (non-)fatal CVD events in breast cancer patients.  
15  
16  
17  
18  
19  
20

### 21 **Study design and population**

22  
23  
24 For WP 1 and 2, the Bragatston study uses a cohort design (Figure 1). The cohort will include  
25 all patients with non-metastatic primary breast cancer treated with radiotherapy at the  
26 University Medical Center Utrecht in Utrecht, the Erasmus MC Cancer Institute in Rotterdam  
27 and the Radboudumc in Nijmegen ( $n \approx 16,000$ ), the Netherlands. Patients with a prevalent  
28 cancer diagnosis will be excluded. From these institutions RT planning CT-scans and clinical  
29 data will be collected starting from the time CT radiotherapy planning was introduced, which  
30 was in 2005 (University Medical Center Utrecht) and 2006 (Erasmus MC Cancer Institute and  
31 Radboudumc) until the end of 2016. The RT planning CT-scans that will be collected are  
32 acquired as part of clinical routine (no contrast enhancement, no ECG-triggering, 120 kVp, in-  
33 plane resolution 0.78-1.37 mm, 3.0 mm slice thickness, 3.0 mm increment).  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 For WP 3, a case-cohort study will be conducted.[34] The case-cohort study will include  
46 all cohort members diagnosed with a CVD event during follow-up, called hereafter cases. In  
47 addition, a random sample will be selected at baseline from the cohort to serve as control. To  
48 increase statistical power, a case-to-control ratio of 1:3 will be applied leading to a random  
49 sample of approximately 600 patients. The power gained by including more than three controls  
50 to one case is little.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Data collection procedures

### Automatic calcification quantification

Cardiovascular calcifications will be measured automatically using a calcium scoring algorithm previously developed in our group.[35] The algorithm uses two consecutive convolutional neural networks (CNN) to label voxels as calcifications in the coronary arteries (left main coronary artery, left anterior descending artery, left circumflex artery and right coronary artery), as well as calcifications in the thoracic aorta and the aortic and mitral valve (leaflets and annulus). The first CNN is used on a large field of view to enable learning from contextual spatial information. This CNN is able to identify calcified voxels and label them according to their anatomical location. The second CNN uses a smaller field of view and analyses the detailed local texture. This CNN can differentiate the true atherosclerotic calcifications among the candidates detected by the first CNN (Figures 2-5).

The algorithm was initially developed to analyse low-dose lung cancer screening CT-scans.[35] Hence the algorithm has been modified to be able to measure calcifications on RT planning CT-scans of breast cancer patients. This procedure has been described in detail elsewhere.[17] The first results show that automatic calcification quantification is possible on RT planning CT-scans of breast cancer patients. Reproducibility of automatically versus manually measured calcium scores was high with linearly weighted kappa values  $\geq 0.84$  and intraclass correlation coefficients  $\geq 0.94$ . [17] For the current project, we will further develop the method to ensure its robustness with respect to image acquisition parameters and thereby enable its applicability in multicenter settings.

CAC, TAC, AVC and MVC will be expressed in volume scores (in  $\text{mm}^3$ ). For routine ECG-gated cardiac CT-scans, CAC is expressed in the Agatston score which also takes the calcification density into account.[36] The CT-scans used in this project are ungated and therefore we will report CAC as modified Agatston score.[37] These modified Agatston scores will be calculated by multiplying the calcification area (in  $\text{mm}^2$ ) by the density score (1, 130–199 Hounsfield Units (HU); 2, 200–299 HU; 3, 300–399 HU; 4, > 399 HU) of the area



1  
2  
3 (calcification density) and summing the lesion scores, in which a minimal lesion definition of  
4  
5 1.5 mm<sup>3</sup> will be maintained to eliminate noise. Based on these scores, patients will be  
6  
7 categorized into the Agatston classification consisting of five categories: 0, 1-10, 11-100, 101-  
8  
9 400, >400 Agatston units.  
10

#### 11 12 13 14 Reference library of manual calcification quantification 15

16  
17 Reference standard for calcium scoring will be defined by manual calcium scoring. Manual  
18  
19 calcium scoring will be done in a subset of planning CT-scans randomly selected per hospital  
20  
21 (UMC Utrecht: n=500; the Erasmus MC Cancer Institute: n=300; Radboudumc: n=200).  
22  
23 Calcifications in the coronary arteries, the aorta and heart valves will be manually identified  
24  
25 and labelled. As is standard procedure, 3D region growing will be used with a threshold of 130  
26  
27 HU.[36] Manual annotation will be performed by observers who will be trained and supervised  
28  
29 by a radiologist (PAJ) with more than 10 years of experience in cardiac CT. Subsequently,  
30  
31 manually annotated calcifications will be quantified to determine calcium scores. In line with  
32  
33 the automatic calcification quantification, CAC, TAC, AVC and MVC will be expressed in  
34  
35 volume scores (in mm<sup>3</sup>). The modified Agatston scores will be calculated as described in the  
36  
37 previous section. Those reference annotations will be used to train the algorithm and to  
38  
39 evaluate its performance.  
40  
41  
42  
43  
44  
45  
46  
47  
48

#### 49 Tumor and treatment characteristics and CVD risk factors

50  
51 Tumor and breast cancer treatment data will be obtained through linkage with the Netherlands  
52  
53 Cancer Registry (NCR) hosted by the Netherlands Comprehensive Cancer Organisation.[38]  
54  
55 Tumor data variables include tumor stage, grade and receptor status and treatment data  
56  
57 variables include type of surgery (breast conserving therapy, mastectomy), radiotherapy  
58  
59 (laterality and radiation fields (if available)), chemotherapy (yes, no), hormonal therapy (yes,  
60  
no) and immunotherapy (yes, no).

1  
2  
3 For WP 3, detailed data on breast cancer treatment and traditional CVD risk factors  
4 present at breast cancer diagnosis will be extracted from hospital and general practice medical  
5 records. The following traditional CVD risk factor data will be collected: age, sex, hypertension,  
6 hypercholesterolaemia, diabetes, smoking and body mass index. Regarding hypertension,  
7 hypercholesterolaemia, diabetes and smoking, a patient will be scored positive when the risk  
8 factor is documented in the hospital medical record or reported by the GP by means of a  
9 questionnaire. Local project members of the participating hospitals will perform linkage with  
10 the NCR and will collect medical record data.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

### 23 Assessment of outcome

24  
25 The primary outcome is the incidence of (non-)fatal CVD events, which is defined as  
26 hospitalization or death from CVD. Death from CVD will be recorded if it is primary cause of  
27 death, meaning this is the disease that leads to death. CVD outcomes will be captured through  
28 linkage with Dutch Hospital Data (DHD), the Dutch Heart Registration (DHR), the Dutch  
29 Population Register (PR) and the National Cause of Death Register (CDR).  
30  
31  
32  
33  
34  
35

36 DHD collects nationwide medical and administrative data for all inpatient and day hospital-  
37 care in the Netherlands (i.e. Hospital Discharge Register). The DHD uses the International  
38 Classification of Disease 9<sup>th</sup> revision (ICD-9).[39] According to this classification, CVD will be  
39 categorized as diseases of the circulatory system (ICD-codes 390-459) and will be further  
40 subcategorized into the following subcategories: hypertensive disease (401-405), ischemic  
41 heart disease (410-414), pericarditis (420), valvular dysfunction (424), cardiomyopathy (425),  
42 arrhythmia (426-427), heart failure (428) and cerebrovascular disease (430-438) and other.  
43  
44 Linkage with the DHD will be facilitated by Statistics Netherlands using the record identification  
45 number.[40] This number is based on a combination of date of birth, sex and postal code and  
46 is assigned to each resident in the Netherlands.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

57 For a more complete data collection on incident CVD, additional linkage with the DHR will  
58 be performed.[41] The DHR collects data on cardiac interventions (e.g. percutaneous coronary  
59  
60

1  
2  
3 intervention) and cardiothoracic surgery (e.g. coronary artery bypass surgery, heart valve  
4 surgery). Linkage will be performed using a combination of identifiers including date of birth,  
5 sex and maiden name.  
6  
7

8  
9 Data on vital status will be obtained from the Dutch Population Register (PR). Causes of  
10 death will be obtained from the CDR maintained by Statistics Netherlands. The register  
11 contains information on all primary and secondary causes of death from all deceased persons  
12 registered in the Netherlands. Causes of death are classified according to ICD-10.[42] CVD  
13 mortality will be categorized as diseases of the circulatory system (ICD-codes I00-I99) and will  
14 be further subcategorized into the following subcategories: hypertensive diseases (I10-13),  
15 ischemic heart diseases (I20-I25), pericarditis (I30-32), valvular dysfunction (I34-38),  
16 cardiomyopathy (I42), arrhythmia (I44-49), heart failure (I50) and cerebrovascular diseases  
17 (I60-I69) and other. Linkage with the PR and CDR will be provided by Statistics Netherlands.  
18 Linkage will be performed by local project members of the participating hospitals. Registries  
19 are complete until the end of 2016 (DHD and DHR) or 2017 (CDR).  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

### 35 **Power calculation**

36  
37  
38 The cohort will consist of approximately 16,000 breast cancer patients (University Medical  
39 Center Utrecht: n≈8,000; Erasmus MC Cancer Institute: n≈5,000; Radboudumc: n≈3,000). A  
40 preliminary study was conducted within the prospective breast cancer cohort Utrecht cohort  
41 for Multiple BREast cancer intervention studies and Long-term evalUation (UMBRELLA).[16,  
42 43] In total, 561 UMBRELLA patients were included and 24% of them had CAC (i.e. Agatston  
43 score>0).[16] By including at least 12,000 patients with an average follow-up of 4 years, 2,880  
44 patients will be expected to have CAC. Assuming 4.5% risk of CVD events after 4 years of  
45 follow-up, 130 CVD events among patients with CAC are expected.[44] In the 9,120 patients  
46 without CAC, with a CVD risk of 1.5% after 4 years, 137 CVD events are expected. Based on  
47 the expected number of at least 200 cases of CVD, a maximum of 20 predictor variables can  
48 be selected for predicting CVD without risk of overfitting.[45]  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Statistical analysis

For WP 1, reliability and agreement will be assessed between automatically and manually determined calcium scores. Results will be presented for the total sample of 1,000 manually and automatically assessed planning CT-scans. In addition, results will be stratified by participating hospital. Agreement between continuous calcium scores will be assessed using Bland-Altman plots and between calcium score categories using proportional agreement. To determine reliability, intraclass correlation coefficients will be calculated for continuous calcium scores. Reliability of calcium categories will be evaluated as Cohen's linearly weighted kappa.

For WP 2, (non-)fatal CVD event rates per 1,000 person years will be calculated for each calcium score category and plotted using Kaplan-Meier survival curves. Differences between categories will be tested with log-rank tests. Cox proportional hazard models will be used to examine the association between calcium scores and (non-)fatal CVD events. Results will be expressed as hazard ratios with their corresponding 95% confidence intervals. Follow-up time will be the underlying time variable starting from the date of RT planning CT-scan and ending at the date of diagnosis of (non-)fatal CVD event or censoring. Censored observations will include non-cardiovascular death, diagnosis of other cancers or end of follow-up, whichever came first. Models will be adjusted for age at RT planning CT-scan and calendar year of RT planning CT-scan. To assess possible effect modification of the association between cardiovascular calcifications and CVD risk by cardiotoxic chemotherapy, left-sided radiotherapy or trastuzumab, stratified analysis will be performed. If evidence for effect modification will be found, models with and without the cross-product term for calcium score and cardiotoxic treatment, will be compared using a log-likelihood ratio test. In order to assess the potential effect of competing events precluding the outcome of interest, sensitivity analyses will be conducted comprising cumulative incidence analysis and competing risk survival analysis as described by Fine and Gray.[46]

1  
2  
3 For WP 3, in univariable cox regression analysis, we will identify which patient  
4 characteristics, traditional CVD risk factors or breast cancer treatment characteristics are  
5 associated with the risk of CVD events. As proposed by Prentice, a weighted cox regression  
6 model will be applied to account for the case-cohort design.[34] Subsequently, a prediction  
7 model will be developed including patient characteristics, traditional CVD risk factors and  
8 treatment characteristics. In a second prediction model, calcium scores will be added and the  
9 incremental value of calcium scores in CVD risk prediction will be evaluated by comparing  
10 discrimination (c-statistics) and reclassification (net reclassification index). To take into account  
11 the potential effect of missing data, a sensitivity analysis will be conducted imputing missing  
12 values of traditional CVD risk factor and breast cancer treatment variables using multiple  
13 imputation.[47]

### 30 **Patient and public involvement**

31  
32 We will conduct a survey among 100 UMBRELLA patients to explore their preferences  
33 regarding disclosure of calcium scores and corresponding CVD risk. Themes that will be  
34 included in the questionnaire are patient's knowledge about CVD risk following a breast cancer  
35 diagnosis, the patient's wish to be informed about CVD risk and preferences on way of  
36 disclosure of CVD risk. The survey will be developed in collaboration with the Dutch Patient  
37 Advocacy Group, a joint initiative from the Dutch Breast Cancer Research Group (BOOG) and  
38 the Dutch Breast Cancer Association (BVN).[48,49] We will inform breast cancer patients  
39 about the results of this project by means of newsletters and presentations at patient  
40 conferences, for example at the annual UMBRELLA patient conference.

### 55 **Timeline**

1  
2  
3 Data collection started in January 2017 and we expect to complete data collection in December  
4  
5 2019. The estimated end date of the study is March 2020.  
6  
7  
8  
9

## 10 **ETHICS AND DISSEMINATION**

11  
12  
13  
14 The study protocol has been reviewed by the Institutional Review Boards (IRBs) of the  
15  
16 University Medical Center Utrecht (reference number: 16-721/C), Erasmus MC Cancer  
17  
18 Institute Rotterdam (MEC-2017-1125) and Radboudumc (2017-3847). The IRBs decided that  
19  
20 the Medical Research Involving Human Subjects Act does not apply to the study. The  
21  
22 requirement for informed consent was waived in accordance with the Code of Conduct for  
23  
24 Medical Research developed by the Federation of Medical Scientific Societies.[50] All data,  
25  
26 with the exception of data provided by Statistics Netherlands, will be stored centrally at the  
27  
28 University Medical Center Utrecht. This dataset will be sent to Statistics Netherlands for  
29  
30 additional linkage. Analyses will be performed in a secure environment of Statistics  
31  
32 Netherlands. The dataset will be anonymized by Statistics Netherlands. The results of the  
33  
34 Bragatston study will be published in international peer-reviewed journals and presented at  
35  
36 scientific conferences.  
37  
38  
39  
40  
41  
42

## 43 **DISCUSSION**

44  
45  
46 The Dutch Bragatston study has been set up to optimize and validate an automated deep  
47  
48 learning algorithm for the identification of breast cancer patients at high risk of CVD based on  
49  
50 the presence of cardiovascular calcifications on RT planning CT. Most breast cancer treatment  
51  
52 guidelines and survival prediction tools mainly focus on tumor characteristics while other  
53  
54 patient characteristics are hardly taken into account. In the era of personalized medicine, given  
55  
56 the high burden of CVD in breast cancer patients it is critical to incorporate patient CVD risk  
57  
58 factors in treatment decisions to find an optimal balance between cancer control and  
59  
60

1  
2  
3 cardiotoxicity. Automated measurement of cardiovascular calcifications on RT planning CT-  
4 scans may be an elegant solution, because RT planning CT-scans are readily available  
5 imaging data and therefore there is no additional (radiation exposure) harm to patients and  
6 only a minimal financial burden to society when calcium scores are measured on these scans.  
7  
8  
9

10  
11 If we find that cardiovascular calcifications measured on RT planning CT-scans are  
12 predictors of CVD risk, the next step will be to investigate how to act on this information and  
13 how to disclose this information to the patient. The dilemma of disclosing calcium scores and  
14 corresponding CVD risk lies in the fact that there is no evidence yet regarding effective risk  
15 reducing interventions. Thus far, no randomized trials have been conducted on the  
16 effectiveness of calcium score-based treatment strategies with CVD morbidity and mortality  
17 reduction as outcome measure.[51] The Risk Or Benefit IN Screening for CArdiovascular  
18 diseases (ROBINSCA) trial is the first ongoing randomized controlled trial investigating the  
19 value of CAC imaging followed by preventive treatment in reducing coronary heart disease-  
20 related mortality and morbidity.[52] In the intervention arm, participants with a CAC Agatston  
21 score above 100 will be treated with statins and angiotensin converting enzyme (ACE)  
22 inhibitors, independent of their blood cholesterol level and blood pressure value. The results  
23 of the ROBINSCA trial might provide important insights potentially relevant for breast cancer  
24 patients with moderate or high CAC score.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 The importance of our study lies in the possibility to introduce targeted preventive  
43 interventions to reduce treatment related CVD. Those include minimization of the mean  
44 radiotherapy heart dose, for example by application of volumetric modulated arc therapy  
45 (VMAT) instead of the standard three dimensional conformal radiation therapy (3DCRT).[53]  
46 Furthermore, chemotherapy-induced cardiotoxicity may be reduced by switching to less  
47 harmful regimens, for example an anthracycline free regime consisting of docetaxel,  
48 carboplatin and trastuzumab has been described for human epidermal growth factor receptor  
49 2 (HER-2) positive breast cancer as a more heart friendly alternative to the standard  
50 regimen.[19, 21, 27] Another strategy is to screen for and treat modifiable cardiovascular risk  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 factors like high blood pressure, diabetes mellitus and high cholesterol levels.[18-20]  
4  
5 Additionally, increased awareness needs to be generated among physicians to identify and  
6  
7 refer breast cancer patients at high risk for CVD to a cardio-oncologist. Cardio-oncology is a  
8  
9 new upcoming discipline focused on cardiovascular care for cancer patients which comprises  
10  
11 CVD risk stratification, close monitoring during and after cancer treatment by means of imaging  
12  
13 techniques or circulating biomarkers and management of a possible CVD event.[18, 20, 27]  
14

15  
16 In conclusion, over the last two decades, advances in breast cancer treatments has led  
17  
18 to improved survival rates. However, these treatments can increase the risk of CVD. To  
19  
20 optimize the individual benefit and risk evaluation of treatment options, we propose to evaluate  
21  
22 the inclusion of information on patient CVD risk. Automated measurement of cardiovascular  
23  
24 calcifications on routinely obtained RT planning CT-scans may be an inexpensive, fast and  
25  
26 accurate solution. The Bragatston study will determine the correlation between those RT  
27  
28 planning CT detected cardiovascular calcifications and the occurrence of CVD events.  
29  
30  
31  
32  
33

### 34 **AUTHORS' CONTRIBUTIONS**

35  
36  
37 MJE, II, SGMV, HJGDB, SAMG, NL, MGAS, AJT, JP, HM, J-PP, HMV set up the study and  
38  
39 protocols. MJE, II, SGMV, SAMG and HMV drafted the manuscript. All authors read and  
40  
41 approved the final manuscript.  
42  
43  
44  
45  
46

### 47 **FUNDING**

48  
49  
50 The work is supported by the Dutch Cancer Society grant number UU 2015-7947.  
51  
52  
53  
54  
55

### 56 **COMPETING INTERESTS**

57  
58  
59  
60



Ivana Išgum: Disclosures not related to the present article: Dr. Išgum received research grants from 1) Pie Medical Imaging BV; 2) the Netherlands Organization for Health Research and Development (ZonMw) with participation of PIE Medical Imaging BV; 3) the Dutch Technology Foundation (STW) within Deep Learning for Medical Image Analysis (DLMedIA) with participation of Pie Medical Imaging BV and Philips Healthcare; 4) Dutch Technology Foundation (STW) with participation of Pie Medical Imaging BV and 3mensio Medical Imaging. In addition, Dr. Išgum has a patent, US Patent Application Number 15/933854, with royalties paid and she is scientific founder and a shareholder of Quantib-U BV.

Joan Penninkhof: Disclosures not related to the present article: Dr. Penninkhof received grants from 1) Accuray Inc, Sunnyvale, USA; 2) Elekta AB, Stockholm, Sweden.

## **WORD COUNT**

3,784

## **ACKNOWLEDGEMENTS**

The authors gratefully acknowledge the Dutch Cancer Society for the financial support. They also acknowledge the members of the Bragatston study group who serve as scientific advisors: Drs. Rhodé M. Bijlsma, Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands. Dr. Erwin L.A. Blezer, Imaging Division, University Medical Center Utrecht, Utrecht, the Netherlands. Prof. dr. Michiel L. Bots, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands and Utrecht University, Utrecht, the Netherlands. Drs. Henrike J. Bretveld, Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands. Dr. Maartje J. Hoening, Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Prof. dr. Luca Incrocci, Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Prof. dr. Pim A. de Jong,

1  
2  
3 Department of Radiology, University Medical Center Utrecht, Utrecht, the Netherlands and  
4 Utrecht University, Utrecht, the Netherlands. Prof. dr. Tim Leiner, Department of Radiology,  
5 University Medical Center Utrecht, Utrecht, the Netherlands and Utrecht University, Utrecht,  
6 the Netherlands. Dr. Julia J. van Tol-Geerdink, Department of Radiation Oncology,  
7 Radboudumc, Nijmegen, the Netherlands. Dr. Ilonca Vaartjes, Julius Center for Health  
8 Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands. Dr.  
9 Wouter B. Veldhuis, Department of Radiology, University Medical Center Utrecht, Utrecht, the  
10 Netherlands. Dr. Janneke Verloop, Department of Research, Netherlands Comprehensive  
11 Cancer Organisation (IKNL), Utrecht, the Netherlands. Prof. dr. Max A. Viergever, Image  
12 Sciences Institute, University Medical Center Utrecht, Utrecht, the Netherlands and Utrecht  
13 University, Utrecht, the Netherlands. Prof. dr. Frank L.J. Visseren, Department of Vascular  
14 Medicine, University Medical Center Utrecht, Utrecht, the Netherlands and Utrecht University,  
15 Utrecht, the Netherlands. Dr. Hester Wessels, Department of Corporate Communications,  
16 University Medical Center Utrecht, Utrecht, the Netherlands.

## 35 REFERENCES

- 37  
38 1 Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality  
39 from breast cancer. *N Engl J Med* 2005;353:1784-92.  
40  
41  
42 2 Plevritis SK, Munoz D, Kurian AW, et al. Association of Screening and Treatment With Breast  
43 Cancer Mortality by Molecular Subtype in US Women, 2000-2012. *JAMA* 2018;319:154-64.  
44  
45  
46 3 Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and  
47 Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency  
48 for Research on Cancer; 2013. <http://globocan.iarc.fr> (accessed 17 May 2018).  
49  
50  
51 4 Gernaat SAM, Ho PJ, Rijnberg N, et al. Risk of death from cardiovascular disease following  
52 breast cancer: a systematic review. *Breast Cancer Res Treat* 2017;164:537-55.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 5 World Health Organization: Global health estimates 2015: deaths by cause, age and sex, by  
4 country and by region, 2000-2015  
5  
6 [http://www.who.int/healthinfo/global\\_burden\\_disease/estimates/en/index1.html](http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html) (accessed 17  
7  
8 May 2018).  
9

10  
11 6 Colzani E, Liljegren A, Johansson AL, et al. Prognosis of patients with breast cancer: causes  
12 of death and effects of time since diagnosis, age, and tumor characteristics. *J Clin Oncol*  
13 2011;29:4014-21.  
14  
15

16  
17  
18 7 Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after  
19 radiotherapy for breast cancer. *N Engl J Med* 2013;368:987-98.  
20  
21

22  
23 8 Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-  
24 year survivors of breast cancer. *J Natl Cancer Inst* 2007;99:365-75.  
25  
26

27  
28 9 Moslehi J. The cardiovascular perils of cancer survivorship. *N Engl J Med* 2013;368:1055-6.  
29  
30

31  
32 10 Harris EE. Cardiac mortality and morbidity after breast cancer treatment. *Cancer Cont*  
33 2008;15:120-9.  
34  
35

36  
37 11 Accordino MK, Neugut AI, Hershman DL. Cardiac effects of anticancer therapy in the  
38 elderly. *J Clin Oncol* 2014;32:2654-61.  
39  
40

41  
42 12 Brower V. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer. *J*  
43 *Natl Cancer Inst* 2013;105:835-6.  
44  
45

46  
47 13 Boekel NB, Jacobse JN, Schaapveld M, et al. Cardiovascular disease incidence after  
48 internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer.  
49 *Br J Cancer* 2018;119:408-41.  
50  
51

52  
53 14 Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for  
54 improvement in cardiovascular risk assessment in intermediate-risk individuals. *JAMA*  
55 2012;308:788-95.  
56  
57  
58  
59  
60

1  
2  
3 15 Mittmann N, Seung SJ, Liu N, et al. Population-based utilization of radiation therapy by a  
4 Canadian breast cancer cohort. *Curr Oncol* 2014;21:e715-7.  
5  
6

7  
8 16 Gernaat SA, Isgum I, de Vos BD, et al. Automatic Coronary Artery Calcium Scoring on  
9 Radiotherapy Planning CT Scans of Breast Cancer Patients: Reproducibility and Association  
10 with Traditional Cardiovascular Risk Factors. *PloS one* 2016;11:e0167925.  
11  
12  
13

14  
15 17 Gernaat SAM, van Velzen SGM, Koh V, et al. Automatic quantification of calcifications in  
16 the coronary arteries and thoracic aorta on radiotherapy planning CT scans of Western and  
17 Asian breast cancer patients. *Radiother Oncol* 2018;127:487-92.  
18  
19  
20

21  
22 18 Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer  
23 treatments and cardiovascular toxicity developed under the auspices of the ESC Committee  
24 for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of  
25 the European Society of Cardiology (ESC). *Eur Heart J* 2016;37:2768-801.  
26  
27  
28  
29

30  
31 19 Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies:  
32 a position statement from the Heart Failure Association of the European Society of Cardiology.  
33  
34  
35  
36  
37  
38

39 20 Armenian SH, Lacchetti C, Barac A, et al. Prevention and Monitoring of Cardiac Dysfunction  
40 in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice  
41 Guideline. *J Clin Oncol* 2017;35:893-911.  
42  
43  
44  
45

46 21 Levis BE, Binkley PF, Shapiro CL. Cardiotoxic effects of anthracycline-based therapy: what  
47 is the evidence and what are the potential harms? *Lancet Oncol* 2017;18:e445-e56.  
48  
49  
50

51 22 Ades F, Zardavas D, Pinto AC, et al. Cardiotoxicity of systemic agents used in breast  
52 cancer. *Breast* 2014;23:317-28.  
53  
54  
55

56 23 Witteles RM, Bosch X. Myocardial Protection During Cardiotoxic Chemotherapy. *Circulation*  
57  
58 2015;132:1835-45.  
59  
60

1  
2  
3 24 Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with  
4 chemotherapy: a systematic review and meta-analysis. *Eur J Cancer* 2013;49:2900-9.

5  
6  
7  
8 25 Bruzzaniti V, Abate A, Pinnaro P, et al. Dosimetric and clinical advantages of deep  
9 inspiration breath-hold (DIBH) during radiotherapy of breast cancer. *J Exp Clin Cancer Res*  
10 2013;32:88.

11  
12  
13  
14  
15 26 Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy,  
16 targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. *Ann Oncol*  
17 2012;23(Suppl 7:vii155-66).

18  
19  
20  
21  
22 27 Comprehensive Cancer Centre the Netherlands (IKNL). Nation-wide Breast Cancer  
23 Guideline. <https://www.oncoline.nl/borstkanker> (accessed 17 May 2018).

24  
25  
26  
27 28 Dang CT, Yu AF, Jones LW, et al. Cardiac Surveillance Guidelines for Trastuzumab-  
28 Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter. *J Clin*  
29 *Oncol* 2016;34:1030-3.

30  
31  
32  
33 29 Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments:  
34 Epidemiology, detection, and management. *CA Cancer J Clin* 2016;66:309-25.

35  
36  
37  
38  
39 30 Correa C, Harris EE, Leonardi MC, et al. Accelerated Partial Breast Irradiation: Executive  
40 summary for the update of an ASTRO Evidence-Based Consensus Statement. *Pract Radiat*  
41 *Oncol* 2017;7:73-9.

42  
43  
44  
45  
46 31 Tison GH, Guo M, Blaha MJ, et al. Multisite extracoronary calcification indicates increased  
47 risk of coronary heart disease and all-cause mortality: The Multi-Ethnic Study of  
48 Atherosclerosis. *J Cardiovasc Comput Tomogr* 2015;9:406-14.

49  
50  
51  
52  
53 32 Jacobs PC, Prokop M, van der Graaf Y, et al. Comparing coronary artery calcium and  
54 thoracic aorta calcium for prediction of all-cause mortality and cardiovascular events on low-  
55 dose non-gated computed tomography in a high-risk population of heavy smokers.  
56 *Atherosclerosis* 2010;209:455-62.  
57  
58  
59  
60

1  
2  
3 33 Willemink MJ, Takx RA, Isgum I, et al. Prognostic value of heart valve calcifications for  
4 cardiovascular events in a lung cancer screening population. *Int J Cardiovasc Imaging*  
5 2015;31:1243-9.  
6  
7  
8

9  
10 34 Prentice RL. A Case-Cohort Design for Epidemiologic Cohort Studies and Disease  
11 Prevention Trials. *Biometrika* 1986;73:1-11.  
12  
13

14  
15 35 Lessmann N, van Ginneken B, Zreik M, et al. Automatic Calcium Scoring in Low-Dose  
16 Chest CT Using Deep Neural Networks With Dilated Convolutions. *IEEE Trans Med Imaging*  
17 2018;37:615-25.  
18  
19  
20

21  
22 36 Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using  
23 ultrafast computed tomography. *J Am Coll Cardiol* 1990;15:827-32.  
24  
25

26  
27 37 Chiles C, Duan F, Gladish GW, et al. Association of Coronary Artery Calcification and  
28 Mortality in the National Lung Screening Trial: A Comparison of Three Scoring Methods.  
29 *Radiology* 2015;276:82-90.  
30  
31  
32

33  
34 38 Netherlands Comprehensive Cancer Organisation. <https://www.iknl.nl> (accessed 17 May  
35 2018).  
36  
37  
38

39 39 World Health Organization. Manual of the International Statistical Classification of Diseases  
40 Injuries and Causes of Death. Ninth Revision, vol 1. Geneva: World Health Organization, 1977.  
41  
42  
43

44 40 Statistics Netherlands. <https://www.cbs.nl/en-gb> (accessed 17 May 2018).  
45  
46

47 41 Dutch Heart Registration. <https://www.nederlandsehartregistratie.nl> (accessed 17 May  
48 2018).  
49  
50

51  
52 42 World Health Organization. International Statistical Classification of Diseases, Injuries and  
53 Related Health Problems. Tenth Revision. Geneva: World Health Organization, 1992.  
54  
55  
56

1  
2  
3 43 Young-Afat DA, van Gils CH, van den Bongard H, et al. The Utrecht cohort for Multiple  
4 BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives,  
5 design, and baseline results. *Breast Cancer Res Treat* 2017;164:445-50.  
6  
7

8  
9  
10 44 Blaha MJ, Budoff MJ, DeFilippis AP, et al. Associations between C-reactive protein,  
11 coronary artery calcium, and cardiovascular events: implications for the JUPITER population  
12 from MESA, a population-based cohort study. *Lancet* 2011;378:684-92.  
13  
14

15  
16  
17 45 Peduzzi P, Concato J, Feinstein AR, et al. Importance of events per independent variable  
18 in proportional hazards regression analysis II. Accuracy and precision of regression estimates.  
19 *J Clin Epidemiol* 1995;48:1503-10.  
20  
21

22  
23  
24 46 Fine JP GR. A proportional hazards model for the subdistribution of a competing risk. *J Am*  
25 *Stat Assoc* 1999;94:496-509.  
26  
27

28  
29  
30 47 Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: J. Wiley & Sons;  
31 1987.  
32

33  
34  
35 48 Dutch Breast Cancer Research Group (BOOG). <https://www.boogstudycenter.nl> (accessed  
36 20 December 2018).  
37

38  
39  
40 49 Dutch Breast Cancer Association (BVN). <https://borstkanker.nl> (accessed 20 December  
41 2018).  
42

43  
44  
45 50 Federation of Medical Scientific Societies. Code of conduct.  
46 [https://www.federa.org/sites/default/files/bijlagen/coreon/gedragcode\\_gezondheidsonderzoek](https://www.federa.org/sites/default/files/bijlagen/coreon/gedragcode_gezondheidsonderzoek.pdf)  
47 [k.pdf](https://www.federa.org/sites/default/files/bijlagen/coreon/gedragcode_gezondheidsonderzoek.pdf) (accessed 17 May 2018).  
48  
49

50  
51  
52 51 Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of  
53 cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology  
54 Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the Am*  
55 *Coll Cardiol* 2010;56:e50-103.  
56  
57  
58  
59  
60

1  
2  
3 52 Vonder M, van der Aalst CM, Vliegenthart R, et al. Coronary Artery Calcium Imaging in the  
4 ROBINSCA Trial: Rationale, Design, and Technical Background. *Acad Radiol* 2017;25:118-  
5 28.  
6  
7  
8

9  
10 53 Taylor CW, Kirby AM. Cardiac Side-effects From Breast Cancer Radiotherapy. *Clin Oncol*  
11 *(R Coll Radiol)* 2015;27:621-9.  
12  
13  
14

## 17 18 **FIGURE TITLES AND LEGENDS**

### 19 20 21 **Figure 1:**

22  
23  
24 Title: Flowchart Bragatston study

25  
26  
27 Legend: Abbreviations: CDR = National cause of death register; CT = computed tomography;  
28 CVD = cardiovascular disease; DHD = Dutch Hospital Data; DHR = Dutch Heart Registration;  
29 NCR = Netherlands Cancer Registry; PR = Dutch Population Register; RT = radiotherapy  
30  
31  
32

### 33 34 35 **Figure 2:**

36  
37 Title: Example of automatic calcification quantification on radiotherapy planning CT-scan using  
38 our deep learning algorithm  
39

40  
41  
42 Legend: Radiotherapy planning CT-scan image showing calcifications in the left anterior  
43 descending artery (in red) and left circumflex artery (in green). Abbreviations: LAD = left  
44 anterior descending artery; LCX = left circumflex artery  
45  
46  
47  
48

### 49 50 51 **Figure 3:**

52  
53 Title: Example of automatic calcification quantification on radiotherapy planning CT-scan using  
54 our deep learning algorithm  
55

56  
57 Legend: Radiotherapy planning CT-scan image showing thoracic aorta calcifications (in  
58 yellow).  
59  
60



**Figure 4:**

Title: Example of automatic calcification quantification on radiotherapy planning CT-scan using our deep learning algorithm



Legend: Radiotherapy planning CT-scan image showing mitral valve calcifications (in orange) and thoracic aorta calcifications (in yellow). Abbreviation: MV = mitral valve


**Figure 5:**

Title: Example of automatic calcification quantification on radiotherapy planning CT-scan using our deep learning algorithm

Legend: Radiotherapy planning CT-scan image showing aortic valve calcifications (in purple) and thoracic aorta calcifications (in yellow). Abbreviation: AV = aortic valve

BRAGATSTON






Title: Example of automatic calcification quantification on radiotherapy planning CT-scan using our deep learning algorithm

Legend: Radiotherapy planning CT-scan image showing calcifications in the left anterior descending artery (in red) and left circumflex artery (in green). Abbreviations: LAD = left anterior descending artery; LCX = left circumflex artery

197x149mm (600 x 600 DPI)


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Example of automatic calcification quantification on radiotherapy planning CT-scan using our deep learning algorithm

Legend: Radiotherapy planning CT-scan image showing thoracic aorta calcifications (in yellow).


206x129mm (600 x 600 DPI)



Title: Example of automatic calcification quantification on radiotherapy planning CT-scan using our deep learning algorithm

Legend: Radiotherapy planning CT-scan image showing mitral valve calcifications (in orange) and thoracic aorta calcifications (in yellow). Abbreviation: MV = mitral valve

164x124mm (600 x 600 DPI)



Title: Example of automatic calcification quantification on radiotherapy planning CT-scan using our deep learning algorithm

Legend: Radiotherapy planning CT-scan image showing aortic valve calcifications (in purple) and thoracic aorta calcifications (in yellow). Abbreviation: AV = aortic valve

192x128mm (600 x 600 DPI)

## STROBE Statement

Checklist of items that should be included in reports of observational studies

Section/Topic	Item No	Recommendation	Reported on Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 3
		(b) Provide in the abstract an informative and balanced summary of what was will be done and what was found	3, 4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5,6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7,13,14
		(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	
Participants	6	<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	7
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
		Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-11
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-11
Bias	9	Describe any efforts to address potential sources of bias	7, 8, 12
Study size	10	Explain how the study size was arrived at	11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8, 10
		(a) Describe all statistical methods, including those used to control for confounding	12,13
		(b) Describe any methods used to examine subgroups and interactions	12,13
		(c) Explain how missing data were addressed	13
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	
Statistical methods	12	<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	12,13
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	

1		(e) Describe any sensitivity analyses	13
2			
3			
4	<b>Section/Topic</b>	<b>Item No</b>	<b>Reported on Page No</b>
5		<b>Recommendation</b>	
6			
7	<b>Results</b>		
8			
9	Participants	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	NA**
10		(b) Give reasons for non-participation at each stage	
11		(c) Consider use of a flow diagram	
12	Descriptive data	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	NA**
13		(b) Indicate number of participants with missing data for each variable of interest	
14		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
15	Outcome data	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	NA**
16		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
17		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
18	Main results	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA**
19		(b) Report category boundaries when continuous variables were categorized	
20		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
21	Other analyses	17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA**
22	<b>Discussion</b>		
23	Key results	18 Summarise key results with reference to study objectives	NA**
24	Limitations	19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	NA**
25	Interpretation	20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	NA**
26	Generalisability	21 Discuss the generalisability (external validity) of the study results	NA**
27	<b>Other Information</b>		
28	Funding	22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.



1 **\*\*Not applicable, because this paper is just about the study protocol**

2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

For peer review only